Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193453 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT00193453 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 69 participants.
The verdict
NCT00193453, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer (NSCLC), in combination with a novel agent cetuximab.
Interventions
- DRUG Docetaxel
- DRUG Cetuximab
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193453
The ClinicalTrials.gov registry entry for NCT00193453 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00193453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193453 about?
NCT00193453 is a clinical study titled "Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer". This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer (NSCLC), in combination with a novel agent cetuximab.
What is the current status of trial NCT00193453?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2005-07. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00193453?
The interventions under investigation include: Docetaxel (DRUG), Cetuximab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00193453?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.